Cervical cancer
Conditions
Interventions
Case series:Subcutaneous injection of pegfilgrastim 24-72 hours after chemotherapy
Sponsors
General Hospital of Chinese People's Liberation Army
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 65 years old; 2. Patients with cervical cancer diagnosed by histopathology; 3. Patients requiring multi-cycle concurrent chemoradiotherapy; 4. Patients without serious complications; 5. Physical status (KPS) Score =70 points; 6. No obvious signs of hematological disease, before the enrollment ANC =1.5×10^9 /L, platelet count =80×10^9/L, Hb = 75 g/L, and no bleeding tendency; 7. Patient signing Informed consent form.
Exclusion criteria
Exclusion criteria: 1. There are currently uncontrollable infections, or systemic antibiotics within 72 hours of receiving chemotherapy; 2. Any abnormal bone marrow hyperplasia and other hematopoietic dysfunction; 3. Patients who have received bone marrow or hematopoietic stem cell transplantation within the past 3 months; 4. Patients with previous malignant tumors who have not been cured or have brain metastases; 5. Liver function tests total bilirubin (TBIL), alanine aminotransferase (ALT), aspartate aminotransferase (AST) >2.5 times the upper limit of normal; if due to liver metastasis, the above indicators >5 times the upper limit of normal; 6. Renal function test: serum creatinine (Cr) > 1.5 times the upper limit of normal; 7. Those who are allergic to this product or other genetically engineered E. coli-derived biological products; 8. Suffering from mental or neurological disorders, unable to cooperate; 9. Researchers believe that it is not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of grade III/IV neutropenia in each cycle of chemotherapy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Dynamic changes in patient ANC (absolute neutrophil count);Incidence of neutropenic fever (FN) in each cycle of chemotherapy;Proportion of dose adjustment of chemotherapy drugs caused by neutropenia in each cycle of chemotherapy;Incidence of delayed chemotherapy caused by neutropenia in each cycle of chemotherapy;Patient hospitalization rate;antibiotic utilization rate;Occurrence and severity of adverse reactions; | — |
Countries
China
Contacts
Public ContactFang Liu
General Hospital of Chinese People's Liberation Army?
Outcome results
None listed